Qihan Biotech
China - HangzhouBiotechnology
Focus: Qihan Biotech is a China-based biotechnology company founded in 2017 specializing in genome editing and cell/organ transplantation platforms targeting immunology and oncology indications. The company is publicly listed with a focused pipeline primarily in cell therapy approaches.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Qihan Biotech
AI assessmentNot HiringNo open roles listed right now. Follow Qihan Biotech to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
6 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
CD33/CLL1 dual CAR-NK cell
AML, AdultClinical Trials (1)
NCT05987696Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia
Phase 1Help build intelligence for Qihan Biotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.